Tag : RADICAL PROSTATECTOMY

Patients with high-risk localized prostate cancer (HR LPC) are at significant risk of developing systemic or local recurrence as well as symptoms and/or death from the disease. While there is a range of treatment options available, including radical prostatectomy (RP), radiation therapy with or without androgen deprivation therapy (ADT), and chemotherapy, there is currently no consensus on the optimal treatment for these patients. The role and benefits of using neoadjuvant or adjuvant ADT in HR LPC patients are also inconclusive, especially among Asia-Pacific patients treated with RP and perioperative hormonal therapy (HT). As such, this retrospective observational study was performed to describe the real-world clinical characteristics and treatment patterns of HR LRPC patients in Japan, South Korea and Taiwan.